Latest oppositions filed by Genentech, Inc.

This table presents recent patent oppositions filed by Genentech, Inc. against its competitors. It outlines key details of each case, including the patent title, filing date and the applicant. This information provides insights into the competitive landscape and highlights active disputes over patent grant within the industry.

Patent NumberTitleApplicantOpposition Date
EP3177645Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of CancerLINDHOFER, HORST, DR.Nov 15, 2021

The following table provides an overview of the latest patents of Genentech, Inc. that has been opposed by its competitors. It provides an insight into the competitive landscape of the industry and highlights the patents that are subject to oppositions.

Patent NumberGrant DateTitleTotal Oppositions
EP2694072Aug 7, 2024Combinations Of Akt Inhibitor Compounds And Abiraterone, And Methods Of Use1
EP4108259Jan 3, 2024Process For Concentration Of Antibodies And Therapeutic Products Thereof1
EP3589661Nov 1, 2023Adjuvant Treatment Of Her2-Positive Breast Cancer4
EP2784084Oct 4, 2023Il-17 A/F Heterologous Polypeptides And Therapeutics Uses Thereof5
EP3597659Mar 1, 2023Prevention Of Disulfide Bond Reduction During Recombinant Production Of Polypeptides9
EP3805248Jan 18, 2023Process For Concentration Of Antibodies And Therapeutic Products Thereof2
EP3401335Jun 30, 2021Composition Comprising Antibody That Binds To Domain Ii Of Her2 And Acidic Variants Thereof5
EP3337812Apr 28, 2021Method For The Reduction Of Host Cell Proteins In Affinity Chromatography4
EP3570884Sep 30, 2020Subcutaneous Her2 Antibody Formulations4
EP1543038Aug 5, 2020Protein Purification1